SCHEMBL1947192

SCHEMBL1947192

Cc1c(C(N)=O)cc(Nc2ncc(F)c(NC3CC(C)(C)N(C)C(C)(C)C3)n2)cc1-n1nnn(C)c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 3/20 0.51
SYK P43405 11/20 0.40
KDR P35968 3/20 0.38
AURKB Q96GD4 2/20 0.38
FLT3 P36888 3/20 0.38
BTK Q06187 3/20 0.38
CDK2 P24941 2/20 0.38
TYK2 P29597 2/20 0.38
JAK3 P52333 2/20 0.38
KIT P10721 2/20 0.38
EGFR P00533 2/20 0.38
CDC7 O00311 1/20 0.38
PLK4 O00444 1/20 0.38
CHEK1 O14757 1/20 0.38
AURKA O14965 1/20 0.38
DCLK1 O15075 1/20 0.38
PDPK1 O15530 1/20 0.38
DAPK3 O43293 1/20 0.38
JAK2 O60674 1/20 0.38
ROCK2 O75116 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1942366 0.94 PRKCQ (0.52) PRKCQSYKKDRAURKBFLT3
SCHEMBL1946093 0.92 PRKCQ (0.50) PRKCQSYKKDRAURKBFLT3
SCHEMBL1945028 0.92 PRKCQ (0.54) PRKCQSYKKDRAURKBFLT3
SCHEMBL1946062 0.89 PRKCQ (0.54) PRKCQSYKKDRAURKBFLT3
SCHEMBL1943926 0.88 PRKCQ (0.53) PRKCQSYKKDRAURKBFLT3
SCHEMBL12564476 0.86 PRKCQ (0.52) PRKCQSYKKDRAURKBFLT3
SCHEMBL1944045 0.86 PRKCQ (0.52) PRKCQSYKFLT3CDK2JAK3
SCHEMBL1943983 0.85 PRKCQ (0.43) PRKCQSYKKDRAURKBFLT3
SCHEMBL1942649 0.84 PRKCQ (0.54) PRKCQSYKKDRAURKBFLT3
SCHEMBL1944983 0.84 PRKCQ (0.56) PRKCQSYKKDRAURKBFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170152246-A1 Protein Kinase C Inhibitors and Uses Thereof MIDCAP FINANCIAL TRUST 2017-06-01 US disclosed
EP-2507227-B1 TETRAZOLONES AS PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2014-10-08 EP disclosed
EP-2507227-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF Rigel Pharmaceuticals, Inc. (US) 2012-10-10 EP disclosed
WO-2011068898-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS, INC. (US) 2011-06-09 WO disclosed
US-20110130415-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS, INC. 2011-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130415-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF PRKCH, PRKCA, PRKCB PRKCQ 5/4885SYK 600/4885KDR 2942/4885
US-20170152246-A1 Protein Kinase C Inhibitors and Uses Thereof PRKCH, PRKCA, PRKCB PRKCQ 5/4885SYK 600/4885KDR 2942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.